Hi Frozen,
I am not sure if that is correct. The company has not managed to control cashburn, has significant expenditure ahead with Peak and is struggling to enter new markets. The volume of prescriptions in the UK and Germany for Althea has been under 50 patients.
They are likely to book a loss of >$20M for the 20-21 Financial year which may create the need for another (3rd) Capital Raise.
The management appear to be confusing revenue with profit which is worrying as there is a lot of investment in this stock.
Althea Group - Future Prospects, page-140
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.001(5.56%) |
Mkt cap ! $7.701M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.8¢ | $21.02K | 1.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2454338 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 587081 | 4 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AGH (ASX) Chart |